Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2024

Pharma News, 2024

Survodutide Improves Liver Disease Progression in More than 80% of Patients with MASH
Survodutide Improves Liver Disease Progression in More than 80% of Patients with MASH

After 48 weeks of treatment with survodutide, patients demonstrated histological improvement, a reduction in liver fat content, and did not experience worsening fibrosis.

Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
On February 26, Neomorph announced that it has inked a $1.46 billion collaboration and licensing agreement with Novo Nordisk to embark on the discovery, development, and commercialization of molec...
FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar
FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar
Simlandi is approved to treat multiple indications, including rheumatoid arthritis and Crohn’s disease.
GSK, pushing back UTI filing by a year, shows antibiotic's gonorrhea potential in phase 3
GSK, pushing back UTI filing by a year, shows antibiotic's gonorrhea potential in phase 3
GSK may have pushed back plans to secure approval for gepotidacin as the first new urinary tract infection (UTI) treatment in 20 years, but fresh phase 3 results have lined up the antibiotic for a...
Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.
Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.
Jacobio Pharma, a clinical-stage oncology company drugging the undruggable targets, announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C ac...
Cleveland Clinic researchers uncover how virus causes cancer, point to potential treatment
Cleveland Clinic researchers uncover how virus causes cancer, point to potential treatment
Cleveland Clinic researchers have discovered a key mechanism used by Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), to induce cancer.
BlossomHill secures $100m for cancer discovery programmes
BlossomHill secures $100m for cancer discovery programmes

BlossomHill Therapeutics has secured $100m in a Series B financing round, a significant move to progress the development of its programmes targeting cancer and autoimmune diseases.

Does yogurt reduce risk of diabetes? The FDA says it might
Does yogurt reduce risk of diabetes? The FDA says it might
Food makers can advertise that regularly eating yogurt may reduce the risk of Type 2 diabetes without objection from the Food and Drug Administration, the agency announced on Friday.
FDA Approves Rybrevant-Chemo Combination for EGFR-Positive Lung Cancer
FDA Approves Rybrevant-Chemo Combination for EGFR-Positive Lung Cancer
The Food and Drug Administration approved Rybrevant plus carboplatin and pemetrexed for locally advanced or metastatic non-small cell lung cancer (NSCLC) that has EGFR exon 20 insertion mutations.
FDA Issues Full Response Letter to Cefepime-taniborbactam Agreement
FDA Issues Full Response Letter to Cefepime-taniborbactam Agreement

The FDA has issued a Complete Response Letter for the New Drug Application of cefepime-taniborbactam, requesting additional chemistry, manufacturing, and controls data.

Ocugen completes dosing of first cohort in trial of gene therapy for Stargardt disease
Ocugen completes dosing of first cohort in trial of gene therapy for Stargardt disease
Biotechnology company Ocugen announced that dosing is complete in the first cohort of its phase 1/2 GARDian clinical trial of OCU410ST, a modifier gene therapy candidate for treatment of Stargardt...
AbbVie and Tentarix partner to develop oncology and immunology biologics
AbbVie and Tentarix partner to develop oncology and immunology biologics
AbbVie and Tentarix Biotherapeutics have announced a multi-year collaboration aimed at developing biologic candidates in oncology and immunology.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand